Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about LEXX, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Arm 1 - DehydraTECH-CBD alone | Type2diabetes | Phase 1 · NCT06648031 | Completed |
| Arm 2 - DehydraTECH-semaglutide alone | Type2diabetes | Phase 1 · NCT06648031 | Completed |
| Arm 3 - DehydraTECH-CBD in combination w | Type2diabetes | Phase 1 · NCT06648031 | Completed |
| Arm 4 - Rybelsus medication (semaglutide | Type2diabetes | Phase 1 · NCT06648031 | Completed |
| Arm 5- Tirzepatide | Type2diabetes | Phase 1 · NCT06648031 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
LEXX holds $3.6M in cash and short-term investments (as of May 31, 2026) and burns about $1.9M/quarter from operations, an estimated runway of 5.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 59 · Elevated
The recurring losses and negative net cash flows raise substantial doubt as to the Company’s ability to continue as a going concern.10-Q, Jul 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LEXX files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LEXX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →